GPC tests satraplatin plus Tarceva in patients with advanced non-small cell lung cancer

By Elaine Rigoli

Tampa, Fla., Aug. 2 - GPC Biotech AG has started a phase 2 randomized trial evaluating the company's lead drug candidate, satraplatin, in combination with Tarceva (erlotinib) as a first-line therapy in patients with inoperable advanced non-small cell lung cancer who are 70 years of age and older.

The phase 2 study is expected to involve more than 20 centers in the United States and Europe and enroll about 120 patients. The primary objective of this study is to evaluate progression-free survival.

The study will also examine overall survival, response rates and safety, the company said in a news release.

A phase 3 registrational trial exploring satraplatin in combination with prednisone as a second-line chemotherapy treatment for patients with hormone-refractory prostate cancer has completed patient enrollment, the company added.

GPC said it continues to open additional clinical studies to explore the potential of satraplatin in a variety of tumor types.

GPC is a biopharmaceutical company with headquarters in Martinsried, Germany.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.